ICO On Other Exchanges
Symbol
Exchange
Venture
OTC US
Frankfurt

ico therapeutics inc (ICO) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ICO THERAPEUTICS INC (ICO)
\

Related News

No related news articles were found.

ico therapeutics inc (ICO) Related Businessweek News

View More BusinessWeek News

ico therapeutics inc (ICO) Details

iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.

Founded in 2005

ico therapeutics inc (ICO) Top Compensated Officers

Co-Founder, CEO, President & Director
Total Annual Compensation: C$205.1K
CFO, Corporate Secretary & Director
Total Annual Compensation: C$50.4K
Compensation as of Fiscal Year 2018.
ico therapeutics inc
Ico Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2018

iCo Therapeutics Inc. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced net loss was CAD 1.702 million compared to CAD 1.237 million a year ago. Basic loss per share was CAD 0.02 compared to CAD 0.01 a year ago.

iCo Therapeutics Inc. Auditor Raises 'Going Concern' Doubt

iCo Therapeutics Inc. filed its Annual on Apr 30, 2019 for the period ending Dec 31, 2018. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

iCo Therapeutics Inc. Announces Termination of Its Product Sublicense Agreement with Immune Pharmaceuticals

iCo Therapeutics Inc. announced that on Friday February 15, 2019 the company delivered written notice terminating, with immediate effect, its product sublicense agreement with Immune Pharmaceuticals, related to iCo-008 (Bertilimumab).

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

ICO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ICO.
View Industry Companies
 

Industry Analysis

ICO

Industry Average

Valuation ICO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 42.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ICO THERAPEUTICS INC, please visit www.icotherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.